Starpharma Holdings (SPL) Short Interest
Starpharma Holdings (ASX:SPL) had 0.03% of shares reported as short positions as of 24 Aug 2026, representing 150,000 shares. Starpharma Holdings operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Starpharma Holdings
Starpharma Holdings is an Australian biotechnology company focused on developing dendrimer technology for pharmaceutical and life science applications. Their proprietary dendrimer platform is used to improve drug delivery, enhance drug efficacy, and create new pharmaceutical products. The company's market position is built on its innovative technology and partnerships with pharmaceutical companies.
Short position
Starpharma Holdings (ASX:SPL) has 0.03% of its shares on issue reported as short positions as of 24 Aug 2026, or about 150,000 shares. Over the past 30 days that figure has fallen 0.22 percentage points, and over 90 days it has fallen 0.06 percentage points. Its highest recorded short interest was 5.89% in September 2013. SPL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4SPL intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Starpharma Holdings
Latest SPL news
All news- Starpharma Holdings (ASX:SPL) Shares Drift As Revenue More Than Doubles - simplywall.st
googlenews
- How Did Starpharma (ASX:SPL) Shift the Healthcare Stocks View?
kalkine
- Is Starpharma (ASX:SPL) Shaping a New Cannabis Stocks View?
kalkine
- Starpharma: FY26 earnings reveal strong revenue growth and improved loss
motleyfool
- 2026 Appendix 4G and Corporate Governance Statement
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss SPL
Start a research thread or post the first pulse update